|Awarded On||August 16, 2017|
|Title||Chemoablation of High-Risk Oral Premalignant Lesions for Sustained Cancer Prevention|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||Texas A&M University System Health Science Center|
|Principal Investigator/Program Director||Robert Tsai|
|Cancer Sites||Head and Neck|
The objective in this proposal is to develop a new, noninvasive product designed to ablate (destroy) lesions in the mouth that are at high risk of becoming malignant (oral premalignant lesions, or OPL) to prevent the development of oral cancer. Stopping cancers from developing, especially when the early (premalignant) lesions can be easily identified, is more cost-effective than treating cancers after they develop. Chemical ablation (in this case, applying drug-containing patches to lesions in the mouth) is a new alternative to surgery or laser therapy for treating premalignant lesions; it is less invasive, is better able to distinguish lesions from nearby healthy tissue, more sustained, and...